Diligence memo · auto-generated · as of July 2, 2026
NuvOx Therapeutics, Inc.
NuvOx Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
NuvOx Therapeutics, Inc. operates in Pharmaceuticals, based in TUCSON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NuvOx Therapeutics, Inc. has raised $1.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.1M on 2023-01-31.
Most recent recorded round closed around 2024-09-10.
Valuation (modeled)modeled
Provath models NuvOx Therapeutics, Inc. at approximately $1.0M (range $178K–$2.6M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.10× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 22 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 4.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 22% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 2% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.